Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $38.00.

OMER has been the topic of a number of research reports. Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. HC Wainwright reduced their price objective on Omeros from $40.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Finally, Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 2nd.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $9.79 on Tuesday. The firm has a market capitalization of $708.60 million, a PE ratio of 13.99 and a beta of 2.55. The firm’s 50-day moving average is $10.27 and its two-hundred day moving average is $11.50. Omeros has a 1 year low of $3.43 and a 1 year high of $17.65.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. Analysts expect that Omeros will post -0.94 EPS for the current fiscal year.

Insider Transactions at Omeros

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director owned 35,067 shares of the company’s stock, valued at $407,127.87. This trade represents a 17.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in Omeros in the first quarter worth approximately $357,000. XTX Topco Ltd purchased a new stake in shares of Omeros in the 2nd quarter valued at approximately $191,000. Invesco Ltd. increased its position in shares of Omeros by 34.1% in the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 29,644 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Omeros by 15.1% in the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Omeros in the 2nd quarter valued at $40,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.